Artificial intelligence chatbot performance in triage of ophthalmic conditions.

BACKGROUND: Timely access to human expertise for affordable and efficient triage of ophthalmic conditions is inconsistent. With recent advancements in publicly available artificial intelligence (AI) chatbots, the lay public may turn to these tools for triage of ophthalmic complaints. Validation studies are necessary to evaluate the performance of AI chatbots as triage tools and inform the public regarding their safety. OBJECTIVE: To evaluate the triage performance of AI chatbots for ophthalmic conditions. DESIGN: Cross-sectional study. SETTING: Single centre. PARTICIPANTS: Ophthalmology trainees, OpenAI ChatGPT (GPT-4), Bing Chat, and WebMD Symptom Checker. METHODS: Forty-four clinical vignettes representing common ophthalmic complaints were developed, and a standardized pathway of prompts was presented to each tool in March 2023. Primary outcomes were proportion of responses with the correct diagnosis listed in the top 3 possible diagnoses and proportion with correct triage urgency. Ancillary outcomes included presence of grossly inaccurate statements, mean reading grade level, mean response word count, proportion with attribution, and most common sources cited. RESULTS: The ophthalmologists in training, ChatGPT, Bing Chat, and the WebMD Symptom Checker listed the appropriate diagnosis among the top 3 suggestions in 42 (95%), 41 (93%), 34 (77%), and 8 (33%) cases, respectively. Triage urgency was appropriate in 38 (86%), 43 (98%), and 37 (84%) cases for ophthalmology trainees, ChatGPT, and Bing Chat, correspondingly. CONCLUSIONS: ChatGPT using the GPT-4 model offered high diagnostic and triage accuracy that was comparable with that of ophthalmology trainees with no grossly inaccurate statements. Bing Chat had lower accuracy and a tendency to overestimate triage urgency.

Visual Function in Pentosan Polysulfate Sodium Maculopathy.

Purpose: Individuals with pentosan polysulfate sodium (PPS) maculopathy commonly report symptoms of prolonged dark adaptation and difficulty reading. We hypothesize that PPS maculopathy causes degradation of visual function not fully captured with visual acuity testing. Methods: Subjects with PPS maculopathy underwent multimodal evaluation of retinal structure and function. Structural changes were graded as moderate or advanced. Patient-reported visual function was assessed with the National Eye Institute Visual Function Questionnaire 39 (NEI-VFQ-39) and Low Luminance Questionnaire (LLQ). Objective functional evaluations included Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA), Pelli-Robson contrast sensitivity, mesopic microperimetry, and dark adaptometry. Functional testing results were correlated with structural disease category. Results: Thirteen patients (26 eyes), median age 62 years (range, 37-76), completed the study. Median ETDRS letter score was 82 (Snellen equivalent 20/25). Median NEI-VFQ-39 and LLQ composite scores were 65 (range, 33-88) and 41 (range, 20-92), respectively. Median contrast sensitivity was 1.65 (range, 0.15-1.95), and median mesopic microperimetry average thresholds and percent reduced thresholds were 26 decibels (range, 0.4-28.6) and 21.6% (range, 0-100%), respectively. Median rod intercept time was 14.1 minutes (range, 4.4-20.0). Eyes with advanced disease based on retinal structure had significantly worse retinal function for several testing modalities. Conclusions: PPS maculopathy causes considerable visual function degradation that is not fully captured with BCVA testing. There was good correlation between other measures of visual function and disease severity. These findings deepen our concern regarding this patient safety issue.

Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.

Importance: Recent studies have linked a vision-threatening maculopathy with long-term use of pentosan polysulfate sodium (PPS). Objective: To evaluate the disease course in PPS-associated maculopathy after drug cessation. Design, Setting, and Participants: In this retrospective case series, patients diagnosed with PPS-associated maculopathy with at least 6 months of follow-up after drug cessation who were treated at the Emory Eye Center, Atlanta, Georgia, or the Casey Eye Institute, Portland, Oregon, were included. Data were collected from April 2014 through November 2019. Main Outcomes and Measures: Change in visual acuity and retinal imaging characteristics over time. Results: Of the 11 included patients, all were female, and the median (interquartile range [IQR]) age was 53 (44-63) years. Participants had a baseline visit at a median (IQR) of 2 (0-4) months after drug cessation and were subsequently observed for a median (IQR) of 12 (8-26) months. The median (IQR) cumulative PPS exposure was 1.97 (1.55-2.18) kg. No eyes exhibited a demonstrable improvement in disease after discontinuing PPS. A total of 9 of 11 patients (82%) reported worsening visual symptoms at the final visit. The mean (SD) logMAR visual acuity was 0.14 (0.23) and 0.14 (0.34) at the baseline and final visit, respectively. Visual acuity improved by 2 or more Snellen lines in 1 eye (5%) and declined by 2 or more Snellen lines in 2 eyes of 1 patient (9%). There was evolution in the pattern of fundus autofluorescence changes and/or optical coherence tomography findings in all eyes. A total of 17 eyes (77%) exhibited expansion of the area of involved tissue. A total of 7 eyes (32%) had macular retinal pigment epithelium atrophy at the baseline visit, and atrophy enlarged after discontinuation of PPS in all 7 eyes, with a median (IQR) growth rate of 0.32 (0.13-0.38) mm per year. Conclusions and Relevance: These retrospective data among 11 patients suggest PPS-associated maculopathy continues to evolve after drug cessation for at least 10 years. In some cases, progressive retinal pigment epithelium atrophy encroaches on the foveal center and thus may pose a long-term threat to central vision.

Combination of lidocaine gel and povidone-iodine to decrease acquired infections in procedures performed using topical anesthesia.

PURPOSE: To test the antiseptic efficacy of povidone-iodine when mixed with topical lidocaine gel. SETTING: Emory School of Medicine, Atlanta, Georgia, USA. DESIGN: Experimental study. METHODS: Staphylococcus epidermidis, Staphylococcus aureus, viridans streptococci (Streptococcus sanguinis), Escherichia coli, and Pseudomonas aeruginosa were grown on blood agar plates with povidone-iodine and/or lidocaine gel. The efficacy of sterilization was quantified by surviving bacterial colony-forming units. RESULTS: Combination of povidone-iodine and lidocaine gel prevented bacterial growth to levels similar to povidone-iodine alone. Application of lidocaine gel to bacteria before povidone-iodine treatment allowed bacterial growth similar to controls not exposed to povidone-iodine. CONCLUSIONS: Povidone-iodine must be applied before lidocaine gel for effective antisepsis, but admixture of povidone-iodine with lidocaine gel was also effective and may reduce the risk of endophthalmitis associated with lidocaine gel use. This strategy offers a practice-changing alternative for preoperative prophylaxis in procedures requiring topical anesthesia.

Pentosan Polysulfate-Associated Macular Disease in Patients With Interstitial Cystitis.

Recent studies have implicated long-term pentosan polysulfate use with vision loss from a newly described macular condition. Affected patients report difficulty with reading and adjusting to dim lighting, and they occasionally develop severe visual disability. Macular changes resemble those seen in age-related macular degeneration, potentially leading to misdiagnosis. The objectives of this Current Commentary are to summarize studies evaluating the association between pentosan polysulfate use and macular disease, to educate pentosan polysulfate prescribers about the clinical manifestations of this condition, and to provide recommendations for screening at-risk patients.

Clinical Outcomes of Patients With Lateral Femoral Cutaneous Nerve Injury After Direct Anterior Total Hip Arthroplasty.

BACKGROUND: Direct anterior total hip arthroplasty (THA) is an increasingly utilized and patient-requested approach for arthroplasty carrying a unique set of complications. Injury to the lateral femoral cutaneous nerve (LFCN) can have a wide range of clinical symptoms ranging from hypesthesia to painful paresthesia. Long-term effects of this injury have not been well studied. We describe duration and severity of these symptoms and correlate their relationship with hip functional scores. METHODS: Between January 2009 and January 2016, 1665 patients with 1871 hips who underwent direct anterior THA by a single surgeon were surveyed for reported outcomes including Douleur Neuropathique 4-Interview (DN4-I), Hip Disability and Osteoarthritis Outcome Score for Joint Replacement (HOOS, JR), and Patient-Reported Outcomes Measurement Information System Short Form Global Health Assessment. The DN4-I was considered positive if 3 (or more) of 7 neuropathic pain symptoms were affirmed at present in the distribution of the LFCN of the affected leg. RESULTS: Six hundred eighty patients accounting for 778 hips completed the survey. Overall, 16% of responders had positive DN4-I scores for continued neuropathic symptoms with a mean time since surgery of 3.9 years at assessment. Twenty-four percent of those responding within 2 years of surgery had positive scores compared with 15% from 2 to 4 years, 14% from 4 to 6 years, and 11% positive from 6 to 8 years after surgery. Of those with positive DN4-I scores, the most commonly affirmed neuropathic symptom was "numbness", reported in 37% of patients. The overall average interval HOOS, JR score was 89.8. There were no differences in HOOS, JR or Patient-Reported Outcomes Measurement Information System scores for patients further out from surgery. CONCLUSION: The most commonly experienced neuropathic symptom in the distribution of the LFCN following direct anterior THA is "numbness" that occurred in 37% of patients with a positive DN4-I score. Neuropathic symptoms improved in patients further out from surgery with pain reported in 11% of patients from 6 to 8 years postoperatively. Neuropathic symptoms significantly improve with time and appear to be independent of hip function scores.